Nasdaq · CIK 0001676725
IDYA IDEAYA Biosciences, Inc.
Insider trading from SEC Form 4. Last filing 4 d ago. Close $36.11 on Oct 9, 2026, +38% from the 52-week low and -15% from the high.
Last 90 days
Net insider value
-$985k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$985k by 1 insider
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
IDYAOct 9, 2026 · close 36.11
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at IDEAYA Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Yujiro S Hata President and CEO sell | $985k 26,338 shares | -4% | - |
Transactions
The last 18 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Yujiro S Hata President and CEO | MOption exercise Common Stock10b5-1 | +26,338 | $4.31 | $114k | 717,033 | 4 d ago |
| Oct 6, 2026 | Yujiro S Hata President and CEO | SOpen-market sale Common Stock10b5-1 | -25,538 | $37.39 | $955k | 691,495 | 4 d ago |
| Oct 6, 2026 | Yujiro S Hata President and CEO | SOpen-market sale Common Stock10b5-1 | -800 | $38.26 | $31k | 690,695 | 4 d ago |
| Oct 6, 2026 | Yujiro S Hata President and CEO | MOption exercise Stock Option (right to buy)derivative10b5-1 | -26,338 | $0.00 | $0 | 23,116 | 4 d ago |
| Jun 24, 2025 | Wendy L Yarno director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Jun 24, 2025 | Jeffrey Stein director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Jun 24, 2025 | Scott W Morrison director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Jun 24, 2025 | Catherine J Mackey director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Jun 24, 2025 | Terry J Rosen director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Jun 24, 2025 | Malcolm Garret Hampton director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Feb 27, 2025 | Darrin Beaupre Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +185,000 | $0.00 | $0 | 185,000 | Feb 28, 2025 |
| Feb 27, 2025 | Stuart Dorman Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Feb 28, 2025 |
| Feb 27, 2025 | Yujiro S Hata President and CEO | AGrant or award Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Feb 28, 2025 |
| Feb 27, 2025 | Douglas B. Snyder SVP, General Counsel | AGrant or award Stock Option (right to buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Feb 28, 2025 |
| Feb 27, 2025 | Michael Anthony White Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +185,000 | $0.00 | $0 | 185,000 | Feb 28, 2025 |
| Feb 27, 2025 | Briseno Andres Ruiz See Remarks | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Feb 28, 2025 |
| Feb 18, 2025 | Yujiro S Hata President and CEO | MOption exercise Common Stock | +12,808 | $19.52 | $250k | 690,695 | Feb 19, 2025 |
| Feb 18, 2025 | Yujiro S Hata President and CEO | MOption exercise Stock Option (right to buy)derivative | -12,808 | $0.00 | $0 | 182,192 | Feb 19, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Darrin BeaupreChief Medical Officer
- Stuart DormanChief Commercial Officer
- Malcolm Garret Hamptondirector
- Yujiro S HataPresident and CEO
- Catherine J Mackeydirector
- Scott W Morrisondirector
- Terry J Rosenceo, officer, director
- Briseno Andres RuizSee Remarks
- Douglas B. SnyderSVP, General Counsel
- Jeffrey Steinceo, president, officer, director
- Michael Anthony WhiteChief Scientific Officer
- Wendy L Yarnodirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.